SCHEMBL19510491

SCHEMBL19510491

COc1ccc2nccn2c1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 3/20 0.39
CDK8 P49336 2/20 0.39
CLK4 Q9HAZ1 2/20 0.39
FLT1 P17948 1/20 0.39
CDK9 P50750 1/20 0.39
LIMK1 P53667 1/20 0.39
RECQL P46063 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
MAP4K4 O95819 3/20 0.36
MAP4K2 Q12851 3/20 0.36
AURKB Q96GD4 3/20 0.36
KDR P35968 2/20 0.36
CSF1R P07333 2/20 0.36
DYRK1A Q13627 2/20 0.36
CHEK1 O14757 1/20 0.36
PRKACA P17612 1/20 0.36
MAP2K1 Q02750 1/20 0.36
ACVR1 Q04771 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25383486 0.80 MC4R (0.38) ROCK1CDK8CLK4FLT1CDK9
SCHEMBL17174248 0.76 CDK8 (0.47) ROCK1CDK8CLK4FLT1CDK9
SCHEMBL3187668 0.73 CDK8 (0.41) ROCK1CDK8CLK4FLT1CDK9
SCHEMBL27385858 0.73 CDK8 (0.41) ROCK1CDK8CLK4FLT1CDK9
SCHEMBL19510399 0.73 CDK8 (0.41) ROCK1CDK8CLK4FLT1CDK9
SCHEMBL5572841 0.73 CDK8 (0.41) ROCK1CDK8CLK4FLT1CDK9
Hydrochloric Acid SCHEMBL19510474 0.72 GAA (0.40) ROCK1CLK4SMN1; SMN2MAP4K4MAP4K2
SCHEMBL19510454 0.72 SYK (0.38) ROCK1CLK4SMN1; SMN2MAP4K4MAP4K2
SCHEMBL25148895 0.71 KDM4E (0.42) ROCK1CDK8CLK4CDK9SMN1; SMN2
SCHEMBL17812868 0.70 CDK8 (0.39) ROCK1CDK8CLK4FLT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3239150-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2020-02-05 EP disclosed
US-10202376-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-02-12 US disclosed
US-20170362223-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-12-21 US disclosed
EP-3239150-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-11-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202376-B2 Heterocyclic compound GRIN2A, GRIN1, GRIN2B ROCK1 4378/4885CDK8 1089/4885CLK4 3894/4885
US-20170362223-A1 HETEROCYCLIC COMPOUND GRIN2A, GRIN1, GRIN2B ROCK1 4378/4885CDK8 1089/4885CLK4 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.